Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

ErbB1 / HER-1 / EGFR tyrosine kinase inhibitors & Non-small-cell lung cancer (NSCLC) (EGFR m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

EGFR-tyrosine kinase inhibitors (TKIs) monotherapy and EGFR tyrosine kinase inhibitors combined with chemotherapy or anti-angiogenesis drugs have significantly prolonged the survival of patients with EGFR-mutant NSCLC.
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126

The application of EGFR tyrosine kinase inhibitors has dramatically changed the therapeutic strategies for advanced and resected NSCLC with EGFR mutations. The 5-year overall survival (OS) rate for advanced NSCLC was close to 40%.
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126

Patients with EGFR exon 20ins showed limited efficacy to EGFR tyrosine kinase inhibitors .
Lu et al. …

References (Sources)

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer
Iwama et al. 2018 Expert Rev Anticancer Ther 18: 267-276
Review
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
Kim et al. 2021b
Review
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Kujtan & Subramanian 2019 Expert Review of Anticancer Therapy 19: 547-559
Review
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126
Review
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Solassol et al. 2019 Biomolecules 9(11): 668
Review
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh 2015 BioDrugs 29(3): 167-83
Review
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
Wang & Li 2019 Onco Targets Ther 12: 6535-6548

AI Chat

7/1/2026

Chat with our artificial intelligence: